Evidence map›Paper›PMID 36251413›Full record

ArticleJournal of clinical gastroenterology2023

Expert Panel Consensus on Clinical Assertion Statements Describing Noninvasive Tools for Diagnosing Nonalcoholic Steatohepatitis.

Ira M Jacobson, Vincent Wai-Sun Wong, Laurent Castera, Quentin M Anstee, Mazen Noureddin, Kenneth Cusi, Stephen A Harrison, Elisabetta Bugianesi, Zobair M Younossi

Open access · greenAbstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical gastroenterology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 9 institutions in 6 countries.

Ira M JacobsonDepartment of Medicine and Therapeutics, NYU Langone Health, New York, NY.
Vincent Wai-Sun WongDepartment of Medicine and Therapeutics.
Laurent CasteraDepartment of Hepatology, Hôpital Beaujon (Beaujon Hospital), Assistance Publique-Hôpitaux de Paris, Clichy.
Quentin M AnsteeTranslational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University.
Mazen NoureddinFatty Liver Program, Karsh Division of Gastroenterology and Hepatology, Cedars Sinai Medical Center, Los Angeles, CA.
Kenneth CusiDivision of Endocrinology, Diabetes and Metabolism, University of Florida.
Stephen A HarrisonRadcliffe Department of Medicine, University of Oxford, Oxford, UK.
Elisabetta BugianesiDepartment of Medical Sciences, Division of Gastroenterology, University of Torino, Torino, Italy.
Zobair M YounossiInova Medicine, Inova Health System.
Assistance Publique – Hôpitaux de Paris · FRCedars-Sinai Medical Center · USChinese University of Hong Kong · CNInova Fairfax Hospital · USNewcastle University · GBNYU Langone Health · USUniversity of Florida · USUniversity of Oxford · GBUniversity of Turin · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

GOALS AND

backgroundA panel of 9 experts in nonalcoholic steatohepatitis gathered to assess multiple components of the diagnostic process. MATERIALS AND

methodsThe Clinical Assertion Statements covered screening of patients with type 2 diabetes for high-risk nonalcoholic fatty liver disease, which-if any-noninvasive tests could determine whether to delay or defer biopsy, whether primary care providers and endocrinologists should routinely calculate Fibrosis-4 (FIB-4) scores in patients with nonalcoholic fatty liver disease or those at risk for it, optimal noninvasive tests to stage fibrosis, the need to consider fibrosis in patients with normal transaminase levels, periodic monitoring for progressive fibrosis, whether patients should undergo biopsy before pharmacotherapy, and the clinical utility of genetic testing. RESULTS AND

conclusionsEvidence was presented to support or refute each Clinical Assertion Statement; the panel voted on the nature of the evidence, level of support, and level of agreement with each Statement. Panel level of agreement and rationale of each Clinical Assertion Statement are reported here.

Indexed as

Diabetes Mellitus, Type 2Non-alcoholic Fatty Liver DiseaseBiopsyHumansLiverLiver Cirrhosis

Identifiers

PMID36251413
PMCPMC9911115
OpenAlexW4306412153

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.